ACETYLCYSTEINE for PCOS
Acetylcysteine is listed as a Phase 2/3 clinical candidate for PCOS per Open Targets, but no mechanistic detail is provided.
Hypothesized mechanism
Mechanism not yet characterized in the substrate.
This is the model’s proposed mechanism from the sources on file, not a demonstrated causal pathway. How well the published record supports it is reflected in the rigor and plausibility dimensions of the score, and traced to the verbatim sources at the foot of the page.
How the score was reached, for this pair
The composite score is the sum of five dimensions, each scored 0 to 2 by the model from the evidence on file. Below is the sub-score this specific pair received on each, with what that dimension measures. It scored 0 of 10 overall, a exploratory reading, from a pathway rated exploratory in strength.
The model’s overall reasoning for this pair is the summary at the top of the page, and the mechanism it proposed is in the section above.
Scored for women. Evidence generated in women (female population). (band F1, ×1.00).
Corroboration
The single claim only states that acetylcysteine is a clinical candidate for PCOS at maximum stage Phase 2/3 per Open Targets. No mechanistic lines of evidence are described, so no convergence can be assessed.
Rigor
The claim is a database annotation of clinical development stage, not a mechanistic model or study with human-relevant data. No experimental or pharmacological evidence is provided to evaluate rigor.
Specificity
The claim does not name any molecular target or describe how acetylcysteine acts. Without a stated target, specificity of action cannot be supported.
Plausibility
No target-phenotype mechanism is given linking acetylcysteine to PCOS pathology. The claim is purely a clinical-stage annotation, offering no basis to judge mechanistic fit.
Consistency
Only one annotation-level claim exists, with no mechanistic signals to compare. Directional consistency cannot be evaluated.
Layers not covered for this pair
Not covered for this pair. This layer holds documented sex-specific pharmacokinetics for a limited set of drugs, and this compound is not among them yet. A blank here means the drug is not covered by the layer, not that no sex difference exists.
More on the sex-specific pharmacokinetics layer and its sources →Not covered for this pair. The cycle-phase layer is seeded for the strongest-evidence cases so far (PMDD), and this pair is not among them yet. A blank here means the pair is not covered by the layer, not that the effect was found to be phase-independent.
More on the cycle-phase layer and its sources →Source evidence · what the pipeline ingested
These are the sources the pipeline ingested to detect and score this signal, the published literature the model actually read, each tagged by study type. Where the model combined findings the claim is marked as a synthesis (S), and where the literature disagrees the contradiction is shown (!).
Every source below belongs to this signal’s evidence arm, Pathway insights. Whel reads each drug-condition pair through four such arms, each held to its own inclusion bar; a signal is surfaced through one of them.
- 1Per Open Targets (retrieved 2026-06-16), ACETYLCYSTEINE (a Small molecule) is a clinical candidate for PCOS (maximum clinical stage PHASE_2_3). Open Targets · mechanistic ↗
- 2In FDA AEMS (the FDA Adverse Event Reporting System, formerly FAERS; retrieved 2026-06-16), 96 report(s) of WEIGHT INCREASED were recorded for ACETYLCYSTEINE among female patients (of 4274 female reports for ACETYLCYSTEINE in the analysed sample). This is a raw adverse-event report count, not a disproportionality statistic or evidence of causation, and is subject to reporting bias and confounding. Read two ways: as a safety consideration, and — because it suggests ACETYLCYSTEINE acts on a system relevant to PCOS — as a mechanistic lead for further investigation, not evidence of benefit. AEMS · adverse-event report ↗
- 3In FDA AEMS (the FDA Adverse Event Reporting System, formerly FAERS; retrieved 2026-06-16), 50 report(s) of ALOPECIA were recorded for ACETYLCYSTEINE among female patients (of 4274 female reports for ACETYLCYSTEINE in the analysed sample). This is a raw adverse-event report count, not a disproportionality statistic or evidence of causation, and is subject to reporting bias and confounding. Read two ways: as a safety consideration, and — because it suggests ACETYLCYSTEINE acts on a system relevant to PCOS — as a mechanistic lead for further investigation, not evidence of benefit. AEMS · adverse-event report ↗
These are the verbatim sources the pipeline surfaced and read; they may not be the full published record for a pair, and the score reflects the strength and agreement of the evidence rather than its volume. The strength of these source types is what the rigor dimension of the score reads off. MATRIX, sex-specific pharmacokinetics, and cycle phase are separate layers the pipeline does not ingest, external cross-references reported beside the score, and they link to their own sources in their sections above.
The primary sources and pipelines this evidence is drawn from →